Interactive Financial Charts Not Available

Anbio Biotechnology (NNNN) | Financial Analysis & Statements

Anbio Biotechnology Ltd. | Small-cap | Healthcare

$42.80

-3.97%

Anbio Biotechnology vs Intuitive Surgical Anbio Biotechnology vs Becton, Dickinson Anbio Biotechnology vs Lemaitre Vascular Anbio Biotechnology vs AtriCure Anbio Biotechnology vs Azenta Anbio Biotechnology vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 18.9M

Total Liabilities 1.7M

Shareholders Equity 17.2M

Debt to Equity 0.10

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Anbio Biotechnology Income Statement From 2021 to 2024

Metric	2024	2023	2022	2021
Revenue i	8.2M	6.7M	23.5M	4.4M
Cost of Goods Sold i	2.3M	3.4M	11.0M	1.9M
Gross Profit i	5.9M	3.4M	12.6M	2.5M
Gross Margin % i	71.9%	50.1%	53.4%	57.4%
Operating Expenses
Research & Development i	454.2K	134.7K	200.0K	0
Selling, General & Administrative i	3.4M	1.3M	2.2M	86.1K
Other Operating Expenses i	-	-	-	-
Total Operating Expenses i	3.9M	1.4M	2.4M	86.1K
Operating Income i	2.0M	2.0M	10.2M	2.5M
Operating Margin % i	24.4%	29.2%	43.3%	55.5%
Non-Operating Items
Interest Income i	337.5K	165.3K	42.2K	0
Interest Expense i	0	0	8.0K	0
Other Non-Operating Income	40.0K	127.4K	-218.7K	79.9K
Pre-tax Income i	2.4M	2.3M	10.0M	2.5M
Income Tax i	0	0	0	0
Effective Tax Rate % i	0.0%	0.0%	0.0%	0.0%
Net Income i	2.4M	2.3M	10.0M	2.5M
Net Margin % i	29.0%	33.6%	42.5%	57.3%
Key Metrics
EBITDA i	2.4M	2.1M	10.3M	2.5M
EPS (Basic) i	-	$0.02	$0.07	$0.03
EPS (Diluted) i	-	$0.01	$0.07	$0.03
Basic Shares Outstanding i	-	143891200	143891200	100000000
Diluted Shares Outstanding i	-	143891200	143891200	100000000

Income Statement Trend

Anbio Biotechnology Balance Sheet From 2021 to 2024

Metric	2024	2023	2022	2021
Assets
Current Assets
Cash & Equivalents i	11.8M	9.7M	7.1M	4.2M
Short-term Investments i	-	0	1.6M	0
Accounts Receivable i	1.1M	1.9M	0	717.5K
Inventory i	-	0	353.9K	0
Other Current Assets	-	-	-	-
Total Current Assets i	18.5M	15.7M	13.9M	4.9M
Non-Current Assets
Property, Plant & Equipment i	-	-	12.1K	-
Goodwill i	-	-	-	-
Intangible Assets i	-	-	-	-
Long-term Investments	-	-	-	-
Other Non-Current Assets	387.4K	60.8K	0	-
Total Non-Current Assets i	387.4K	62.1K	15.0K	0
Total Assets i	18.9M	15.8M	14.0M	4.9M
Liabilities
Current Liabilities
Accounts Payable i	1.6M	827.2K	1.4M	1.9M
Short-term Debt i	-	-	-	-
Current Portion of Long-term Debt	-	-	-	-
Other Current Liabilities	-	-1	-	-
Total Current Liabilities i	1.7M	993.1K	1.4M	2.4M
Non-Current Liabilities
Long-term Debt i	-	-	-	-
Deferred Tax Liabilities i	-	-	-	-
Other Non-Current Liabilities	-	-	-	-
Total Non-Current Liabilities i	0	0	0	0
Total Liabilities i	1.7M	993.1K	1.4M	2.4M
Equity
Common Stock i	14.2K	14.2K	0	0
Retained Earnings i	17.2M	14.8M	12.5M	2.5M
Treasury Stock i	-	-	-	-
Other Equity	-	-	-	-
Total Shareholders Equity i	17.2M	14.8M	12.5M	2.5M
Key Metrics
Total Debt i	0	0	0	0
Working Capital i	16.8M	14.8M	12.5M	2.5M

Balance Sheet Composition

Anbio Biotechnology Cash Flow Statement From 2021 to 2024

Metric	2024	2023	2022	2021
Operating Activities
Net Income i	2.4M	2.3M	10.0M	2.5M
Depreciation & Amortization i	0	12.1K	6.3K	0
Stock-Based Compensation i	-	-	-	-
Working Capital Changes i	1.6M	-1.9M	-623.3K	1.7M
Operating Cash Flow i	3.9M	316.5K	9.4M	4.2M
Investing Activities
Capital Expenditures i	-	-	-	-
Acquisitions i	-	-	-	-
Investment Purchases i	-35.5M	-18.5M	-16.1M	-
Investment Sales i	35.8M	20.3M	14.6M	-
Investing Cash Flow i	337.1K	1.7M	-1.5M	-
Financing Activities
Share Repurchases i	-	-	-	-
Dividends Paid i	-	-	-	-
Debt Issuance i	-	-	-	-
Debt Repayment i	-	-	-	-
Financing Cash Flow i	-344.6K	-42.8K	-	-
Free Cash Flow i	2.1M	898.4K	4.4M	4.2M
Net Change in Cash i	3.9M	2.0M	7.9M	4.2M

Cash Flow Trend

Anbio Biotechnology Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 713.33

Price to Book 105.16

Price to Sales 229.51

Profitability Ratios

Profit Margin 28.99%

Operating Margin -68.64%

Return on Equity 14.83%

Return on Assets 7.18%

Financial Health

Current Ratio 10.71

Debt to Equity 0.00

Per Share Data

EPS (TTM) $0.06

Book Value per Share $0.41

Revenue per Share $0.19

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
nnnn	1.9B	713.33	105.16	14.83%	28.99%	0.00
Intuitive Surgical	173.2B	67.57	9.70	16.04%	28.51%	0.00
Becton, Dickinson	50.5B	34.25	2.00	5.89%	7.18%	76.34
Lemaitre Vascular	1.8B	41.14	5.27	13.77%	19.96%	53.33
AtriCure	1.7B	-36.22	3.68	-7.85%	-7.27%	16.63
Azenta	1.5B	-10.47	0.87	-8.58%	-9.77%	3.16

Financial data is updated regularly. All figures are in the company's reporting currency.